Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anaise Blouet"'
Autor:
Laurent Garderet, Hafida Ouldjeriouat, Mohamed-Amine Bekadja, Elisabeth Daguenet, Laure Vincent, Damien Roos Weil, Marguerite Vignon, Mohamad Mohty, Julie Abraham, Martine Escoffre-Barbe, Bruno Lioure, redhouane Ahmed Nacer, Denis Caillot, Clara Mariette, Lionel Karlin, Pierre Morel, Lila Gilis, Emanuelle Leray, Anaise Blouet, Nicole Raus, Marie Robin, jean Jacques Boffa, Pierre Ronco, Marie Thérèse Rubio, Jerome Lambert, Jérôme Cornillon
Publikováno v:
Blood. 140:7219-7221
Autor:
Anaise Blouet, Amine Umlil, Delphine Bourneau-Martin, Nina Duret-Aupy, Guillaume Drablier, Cécile Conte, Marie Briet, Sami Kettani, Laurence Lagarce
Publikováno v:
Therapies. 74:675-677
Autor:
Sophie de Guibert, Lauren Veronese, Loic Ysebaert, Charles Herbaux, Olivier Tournilhac, Emmanuelle Tchernonog, Anne-Sophie Michallet, Florence Cymbalista, Damien Roos-Weil, Bruno Pereira, Jehan Dupuis, Pierre Feugier, Anne Calleja, Florian Bouclet, Caroline Dartigeas, Sandy Amorim, Anaise Blouet, Marie-Sarah Dilhuydy, Florence Nguyen-Khac, Pierre Morel, Nataliya Dmytruck, Kamel Laribi, Alain Delmer, Thérèse Aurran, Bénédicte Hivert, Romain Guieze
Publikováno v:
Annals of Hematology
Annals of Hematology, Springer Verlag, 2021, 100 (4), pp.987-993. ⟨10.1007/s00277-021-04419-w⟩
Annals of Hematology, Springer Verlag, 2021, 100 (4), pp.987-993. ⟨10.1007/s00277-021-04419-w⟩
The BCL2 inhibitor venetoclax is transforming the management of patients with chronic lymphocytic leukemia (CLL), given its high efficacy in relapsed/refractory CLL as observed in both early-phase and randomized clinical trials. The present study aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bcfa17e3bf9239371765d63d44c9ea8
https://hal.uca.fr/hal-03441025
https://hal.uca.fr/hal-03441025
Autor:
Anaise Blouet, Elisabeth Daguenet, Lionel Karlin, Jérôme Cornillon, Pierre Morel, Lila Gilis, Emanuelle Leray, Hafida Ouldjeriouat, Laurent Garderet, Mohamed Amine Bekadja, Marguerite Vignon, Redhouane Ahmed Nacer, Mohamad Mohty, Jean Jacques Boffa, Marie Robin, Denis Caillot, Marie-Thérèse Rubio, Martine Escoffre-Barbe, Nicole Raus, Damien roos Weil, Bruno Lioure, Pierre Ronco, Clara Mariette, Laure Vincent, Julie Abraham
Publikováno v:
Blood. 136:38-39
Background: High dose melphalan (HDM) followed by autologous hematopoietic stem cell transplantation (ASCT) is widely used in multiple myeloma (MM) patients as upfront and salvage therapy. However, the safety and efficacy of ASCT in patients with ren
Autor:
Pierre Morel, Laure Farnault, Thérèse Aurran, Caroline Dartigeas, Sandy Amorim, Alain Delmer, Isabelle Plantier, Florian Bouclet, Loic Ysebaert, Sophie de Guibert, Olivier Tournilhac, Charles Herbaux, Bénédicte Hivert, Anaise Blouet, Marie-Sarah Dilhuydy, Romain Guieze, Emmanuelle Tchernonog, Anne Calleja, Jacques-Olivier Bay, Anne Lavaud, Florence Cymbalista, Damien Roos-Weil, Anne-Sophie Michallet, Natalia Dmytruk, Kamel Laribi, Pierre Feugier, Jehan Dupuis
Publikováno v:
Blood. 132:5549-5549
Introduction.The BCL-2 inhibitor venetoclax has demonstrated high efficiency in relapsed/refractory (R/R) CLL patients with an overall response rate (ORR) of 79%, regardless of the TP53gene status. Venetoclax has then been EMEA-approved for CLL patie
Autor:
Anaïse Blouet, Marie-Christine Rousselet, Yannick Le Bris, Bénédicte Ribourtout, Anne Bouvier, Laurane Cottin, Rébecca Jouanneau-Courville, Odile Blanchet, Valérie Ugo, Damien Luque Paz
Publikováno v:
HemaSphere, Vol 2, Iss 1 (2018)
Externí odkaz:
https://doaj.org/article/a2b869712a704db6b06ab659aab64af7